PTC Acquires Near-Approval ST-920 Fabry Gene Therapy in Bankruptcy Auction

PTC Therapeutics acquires BLA-stage ST-920, a one-time AAV gene therapy for Fabry disease, with potential U.S. launch in 2027 and strong clinical data.